AB
NRIX icon

Amalgamated Bank’s Nurix Therapeutics NRIX Stock Holding History

Amalgamated Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,149
Closed -$60K – 2418
2025
Q4 		$60K Buy
3,149
+556
+21% +$7.99K ﹤0.01% 1790
2025
Q3 		$24K Hold
2,593
– – ﹤0.01% 2049
2025
Q2 		$30K Hold
2,593
– – ﹤0.01% 1971
2025
Q1 		$31K Buy
2,593
+411
+19% +$6.87K ﹤0.01% 1934
2024
Q4 		$41K Hold
2,182
– – ﹤0.01% 1885
2024
Q3 		$49K Buy
2,182
+511
+31% +$11.6K ﹤0.01% 1853
2024
Q2 		$35K Buy
1,671
+132
+9% +$2.06K ﹤0.01% 1942
2024
Q1 		$23K Sell
1,539
-2,507
-62% -$27K ﹤0.01% 2081
2023
Q4 		$42K Sell
4,046
-458
-10% -$3.14K ﹤0.01% 2329
2023
Q3 		$35K Hold
4,504
– – ﹤0.01% 2399
2023
Q2 		$45K Sell
4,504
-204
-4% -$2.08K ﹤0.01% 2366
2023
Q1 		$42K Sell
4,708
-1,133
-19% -$11.8K ﹤0.01% 2371
2022
Q4 		$64K Hold
5,841
– – ﹤0.01% 2316
2022
Q3 		$76K Buy
5,841
+226
+4% +$3.58K ﹤0.01% 2275
2022
Q2 		$71K Buy
5,615
+634
+13% +$7.19K ﹤0.01% 2319
2022
Q1 		$70K Buy
+4,981
New +$88.4K ﹤0.01% 2318

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Amalgamated Bank's NRIX Position: Q1 2026 in Review

Amalgamated Bank sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 3,149 shares — an estimated $60K sold.

Amalgamated Bank first reported a position in NRIX in Q1 2022 and held it in 16 quarters. The position peaked at $76K in Q3 2022. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Amalgamated Bank reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,149 Nurix Therapeutics shares in Q1 2026, an estimated $60K.
  • Amalgamated Bank first reported a position in Nurix Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Nurix Therapeutics position peaked at $76K in Q3 2022.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.